Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
uPAR-Biparatopic MARC
- Development stage
- Preclinical
- Lead developer
- Modulari-T
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
uPAR-Biparatopic MARC is a preclinical-stage cell therapy developed by Modulari-T for the treatment of renal disorders, specifically focal segmental glomerulosclerosis (FSGS). The therapy utilizes the company's proprietary MARC (Modular Antibody Receptor Complex) platform, which is an engineered receptor system designed to provide enhanced signaling and target recognition compared to traditional CAR-T architectures. This specific asset is biparatopic, meaning it is engineered to recognize and bind to two distinct epitopes on the urokinase-type plasminogen activator receptor (uPAR). uPAR is a membrane-bound protein that, when pathologically elevated or activated, is associated with podocyte injury and the progression of proteinuric kidney diseases like FSGS. By targeting uPAR-expressing cells or modulating uPAR-mediated pathways, this cell therapy aims to address the underlying drivers of renal damage.
- Other names
- uPAR-Biparatopic MARC cell therapy
02
Targets
PLAUR (Urokinase plasminogen activator receptor)
Beyond the preview
Go deeper on uPAR-Biparatopic MARC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on uPAR-Biparatopic MARC.